SARS-CoV-2 Infection of Airway Epithelial Cells

키워드

참고문헌 (112)

1. Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
2. Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
3. Wu F, "A new coronavirus associated with human respiratory disease in China", Nature, 579, pp.265~269 (2020)
4. Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
5. Larsen JR, "Modeling the onset of symptoms of COVID-19", Front Public Health, 8, pp.473~ (2020)
6. Riphagen S, "Hyperinflammatory shock in children during COVID-19 pandemic", Lancet, 395, pp.1607~1608 (2020)
7. Richard M, "SARS-CoV-2 is transmitted via contact and via the air between ferrets", Nat Commun, 11, pp.3496~ (2020)
8. Zhang R, "Identifying airborne transmission as the dominant route for the spread of COVID-19", Proc Natl Acad Sci U S A, 117, pp.14857~14863 (2020)
9. Zou L, "SARS-CoV-2 viral load in upper respiratory specimens of infected patients", N Engl J Med, 382, pp.1177~1179 (2020)
10. Vlek ALM, "Combined throat", nasal swab sampling for SARSCoV-2 is equivalent to nasopharyngeal sampling, 2021, pp.40, 193~195
11. Wang H, "Nasopharyngeal swabs are more sensitive than oropharyngeal swabs for COVID-19 diagnosis and monitoring the SARS-CoV-2 load", Front Med(Lausanne), 7, pp.334~ (2020)
12. Sungnak W, "SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes", Nat Med, 26, pp.681~687 (2020)
13. Monica Fung, "Zoonotic coronavirus epidemics", Annals of Allergy, Asthma & Immunology, 126(4), pp.321~337 (2021), Elsevier BV[DOI]
14. Peiris JS, "The severe acute respiratory syndrome", N Engl J Med, 349, pp.2431~2441 (2003)
15. Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
16. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
17. Bertram S, "Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts", PLoS One, 7, pp.e35876~ (2012)
18. Du M, "Multiomics evaluation of gastrointestinal and other clinical characteristics of COVID-19", Gastroenterology, 158, pp.2298.e7~2301.e7 (2020)
19. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
20. Oreste Gallo, "The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection", Mucosal Immunology, 14(2), pp.305~316 (2021), Springer Science and Business Media LLC[DOI]
21. Bedford J, "COVID-19 : towards controlling of a pandemic", Lancet, 395, pp.1015~1018 (2020)
22. Gordon DE, "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing", Nature, 583, pp.459~468 (2020)
23. Patel VB, "Role of the ACE2", angiotensin 1–7 axis of the renin-angiotensin system in heart failure, 2016, pp.118, 1313~1326
24. Lee IT, "ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs", Nat Commun, 11, pp.5453~ (2020)
25. Imai Y, "Angiotensinconverting enzyme 2 protects from severe acute lung failure", Nature, 436, pp.112~116 (2005)
26. Kuba K, "A crucial role of angiotensin converting enzyme 2(ACE2)in SARS coronavirus-induced lung injury", Nat Med, 11, pp.875~879 (2005)
27. Huang F, "Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients", Nat Commun, 5, pp.3595~ (2014)
28. Yan R, "Structural basis for the recognition of SARS-CoV-2 by fulllength human ACE2", Science, 367, pp.1444~1448 (2020)
29. Raj VS, "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC", Nature, 495, pp.251~254 (2013)
30. Ziegler CGK, "SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues", Cell, 181, pp.1016~1035 (2020)
31. Tata PR, "Dedifferentiation of committed epithelial cells into stem cells in vivo", Nature, 503, pp.218~223 (2013)
32. Chen M, "Elevated ACE-2 expression in the olfactory neuroepithelium : implications for anosmia and upper respiratory SARS-CoV-2 entry and replication", Eur Respir J, 56, pp.2001948~ (2020)
33. Chua RL, "COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis", Nat Biotechnol, 38, pp.970~979 (2020)
34. Coutard B, "The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade", Antiviral Res, 176, pp.104742~ (2020)
35. Lukassen S, "SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells", EMBO J, 39, pp.e105114~ (2020)
36. Aguiar JA, "Gene expression and in situ protein profiling of candidate SARS-CoV-2receptors in human airway epithelial cells and lung tissue", Eur Respir J, 56, pp.2001123~ (2020)
37. Cantuti-Castelvetri L, "Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity", Science, 370, pp.856~860 (2020)
38. Daly JL, "Neuropilin-1 is a host factor for SARS-CoV-2 infection", Science, 370, pp.861~865 (2020)
39. Drożdżal S, "FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2(COVID-19)therapy", Drug Resist Updat, 53, pp.100719~ (2020)
40. Milewska A, "Replication of severe acute respiratory syndrome coronavirus 2 in human respiratory epithelium", J Virol, 94, pp.e00957~20 (2020)
41. Sallenave JM, "Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in COVID-19 : key therapeutic targets", Front Immunol, 11, pp.1229~ (2020)
42. Fiege JK, "Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium", PLoS Pathog, 17, pp.e1009292~ (2021)
43. Hamming I, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", J Pathol, 203, pp.631~637 (2004)
44. Harcourt J, "Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, united states", Emerg Infect Dis, 26, pp.1266~1273 (2020)
45. Blanco-Melo D, "Imbalanced host response to SARS-CoV-2 drives development of COVID-19", Cell, 181, pp.1036~1045 (2020)
46. Gamage AM, "Infection of human nasal epithelial cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles", PLoS Pathog, 16, pp.e1009130~ (2020)
47. Zhu N, "Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells", Nat Commun, 11, pp.3910~ (2020)
48. Hao S, "Long-term modeling of SARS-CoV-2 infection of in vitro cultured polarized human airway epithelium", MBio, 11, pp.e02852~20 (2020)
49. Ehre C, "SARS-CoV-2 infection of airway cells", N Engl J Med, 383, pp.969~ (2020)
50. Ravindra NG, "Single-cell longitudinal analysis of SARS-CoV-2 infection in human bronchial epithelial cells", bioRxiv, ~ (2020)
51. Xie X, "An infectious cDNA clone of SARS-CoV-2", Cell Host Microbe, 27, pp.841~848 (2020)
52. Lamers MM, "An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells", EMBO J (2020)[DOI]
53. Lamers MM, "SARS-CoV-2 productively infects human gut enterocytes", Science, 369, pp.50~54 (2020)
54. Salahudeen AA, "Progenitor identification and SARS-CoV-2 infection in human distal lung organoids", Nature, 588, pp.670~675 (2020)
55. Han Y, "Identification of SARS-CoV-2 inhibitors using lung and colonic organoids", Nature, 589, pp.270~275 (2021)
56. Mulay A, "SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery", bioRxiv, ~ (2020)
57. Matheson NJ, "How does SARS-CoV-2 cause COVID-19", Science, 369, pp.510~511 (2020)
58. Yao Y, "Expression of ACE2 in airways : Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases", Clin Exp Allergy, 50, pp.1313~1324 (2020)
59. Saheb Sharif-Askari N, "Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD", Mol Ther Methods Clin Dev, 18, pp.1~6 (2020)
60. Bunyavanich S, "Nasal gene expression of angiotensin-converting enzyme 2 in children and adults", JAMA, 323, pp.2427~2429 (2020)
61. Schouten LR, "Age-dependent differences in pulmonary host responses in ARDS : a prospective observational cohort study", Ann Intensive Care, 9, pp.55~ (2019)
62. Ortiz ME, "Heterogeneous expression of the SARS-coronavirus-2 receptor ACE2 in the human respiratory tract", EBioMedicine, 60, pp.102976~ (2020)
63. Brodin P, "Immune determinants of COVID-19 disease presentation and severity", Nat Med, 27, pp.28~33 (2021)
64. Bajaj V, "Aging, immunity, and COVID-19 : how age influences the host immune response to coronavirus infections", Front Physiol, 11, pp.571416~ (2021)
65. Inde Z, "Agedependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19disease severity", bioRxiv 2020, ~ (2020)
66. Meftahi GH, "The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection : the contribution of"inflame-aging"", Inflamm Res, 69, pp.825~839 (2020)
67. Donoghue M, "A novel angiotensin-converting enzyme-related carboxypeptidase(ACE2)converts angiotensin I to angiotensin 1-9", Circ Res, 87, pp.E1~E9 (2000)
68. Crackower MA, "Angiotensin-converting enzyme 2 is an essential regulator of heart function", Nature, 417, pp.822~828 (2002)
69. Hamming I, "The emerging role of ACE2 in physiology and disease", J Pathol, 212, pp.1~11 (2007)
70. Zhang H, "Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium", Am J Respir Crit Care Med, 202, pp.219~229 (2020)
71. Leung JM, "ACE-2expression in the small airway epithelia of smokers and COPD patients : implications for COVID-19", Eur Respir J, 55, pp.55~ (2020)
72. Purkayastha A, "Direct exposure to SARS-CoV-2 and cigarette smoke increases infection severity and alters the stem cell-derived airway repair response", Cell Stem Cell, 27, pp.869.e4~875.e4 (2020)
73. Kimura H, "Type 2inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells", J Allergy Clin Immunol, 146, pp.80.e8~88.e8 (2020)
74. Sajuthi SP, "Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium", Nat Commun, 11, pp.5139~ (2020)
75. Jackson DJ, "Association of respiratory allergy, asthma, and expression of the SARS-CoV-2receptor ACE2", J Allergy Clin Immunol, 146, pp.203.e3~206.e3 (2020)
76. Wang M, "Inflammatory endotypes of CRSwNP and responses to COVID-19", Curr Opin Allergy Clin Immunol, 21, pp.8~15 (2021)
77. Hai Wang, "Regional differences in ACE2 expression in the sinonasal mucosa of adult Chinese patients with chronic rhinosinusitis", Allergy, 76(5), pp.1565~1568 (2021), Wiley[DOI]
78. Ming Wang, "Distinct expression of SARS‐CoV‐2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps", Allergy, 76(3), pp.789~803 (2021), Wiley[DOI]
79. Narasaraju T, "Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19", Ann Intern Med, 173, pp.323~324 (2020)
80. Chen IY, "Severe acute respiratory syndrome coronavirus viroporin 3a activates the nlrp3 inflammasome", Front Microbiol, 10, pp.50~ (2019)
81. Fink SL, "Apoptosis, pyroptosis, and necrosis : mechanistic description of dead and dying eukaryotic cells", Infect Immun, 73, pp.1907~1916 (2005)
82. Tay MZ, "The trinity of COVID-19 : immunity, inflammation and intervention", Nat Rev Immunol, 20, pp.363~374 (2020)
83. Lazear HM, "Shared and distinct functions of type i and type iii interferons", Immunity, 50, pp.907~923 (2019)
84. Hur S, "Double-stranded RNA sensors and modulators in innate immunity", Annu Rev Immunol, 37, pp.349~375 (2019)
85. Sokol CL, "The chemokine system in innate immunity", Cold Spring Harb Perspect Biol, 7, pp.a016303~ (2015)
86. Hadjadj J, "Impaired type I interferon activity and inflammatory responses in severe COVID-19patients", Science, 369, pp.718~724 (2020)
87. Arunachalam PS, "Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans", Science, 369, pp.1210~1220 (2020)
88. Lucas C, "Longitudinal analyses reveal immunological misfiring in severe COVID-19", Nature, 584, pp.463~469 (2020)
89. Moore JB, "Cytokine release syndrome in severe COVID-19", Science, 368, pp.473~474 (2020)
90. Sa Ribero M, "Interplay between SARS-CoV-2 and the type I interferon response", PLoS Pathog, 16, pp.e1008737~ (2020)
91. Bost P, "Host-viral infection maps reveal signatures of severe COVID-19 patients", Cell, 181, pp.1475.e12~1488.e12 (2020)
92. Liao M, "Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19", Nat Med, 26, pp.842~844 (2020)
93. Lee JS, "Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19", Sci Immunol, 5, pp.eabd1554~ (2020)
94. Chen G, "Clinical and immunological features of severe and moderate coronavirus disease 2019", J Clin Invest, 130, pp.2620~2629 (2020)
95. Hirano T, "COVID-19 : a new virus, but a familiar receptor and cytokine release syndrome", Immunity, 52, pp.731~733 (2020)
96. Zhuang MW, "Increasing host cellular receptorangiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV(or SARS-CoV-2)infection", J Med Virol, 92, pp.2693~2701 (2020)
97. Onabajo OO, "Interferons and viruses induce a novel truncated ACE2 isoform and not the fulllength SARS-CoV-2 receptor", Nat Genet, 52, pp.1283~1293 (2020)
98. Zhang H, "Angiotensin-converting enzyme 2(ACE2)as a SARSCoV-2 receptor : molecular mechanisms and potential therapeutic target", Intensive Care Med, 46, pp.586~590 (2020)
99. Monteil V, "Inhibition of SARS-CoV-2 infections in engineered human tissues using clinicalgrade soluble human ACE2", Cell, 181, pp.905.e7~913.e7 (2020)
100. Khan A, "A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome", Crit Care, 21, pp.234~ (2017)
101. Zhang H, "Recombinant human ACE2 : acing out angiotensin II in ARDS therapy", Crit Care, 21, pp.305~ (2017)
102. Wang K, "CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells", Signal Transduct Target Ther, 5, pp.283~ (2020)
103. Bian H, "Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial", medRxiv 2020 doi: 10.1101, 2020 (2020)
104. Lau SKP, "Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus : implications for pathogenesis and treatment", J Gen Virol, 94, pp.2679~2690 (2013)
105. Cameron MJ, "Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome", J Virol, 81, pp.8692~8706 (2007)
106. Felgenhauer U, "Inhibition of SARS-CoV-2 by type I and type III interferons", J Biol Chem, 295, pp.13958~13964 (2020)
107. Lokugamage KG, "Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV", J Virol, 94, pp.e01410~e01420 (2020)
108. Mantlo E, "Antiviral activities of type I interferons to SARS-CoV-2 infection", Antiviral Res, 179, pp.104811~ (2020)
109. Andreakos E, "Interferon-λs : front-line guardians of immunity and homeostasis in the respiratory tract", Front Immunol, 8, pp.1232~ (2017)
110. Broggi A, "Type III interferons : balancing tissue tolerance and resistance to pathogen invasion", J Exp Med, 217, pp.217~ (2020)
111. Prokunina-Olsson L, "COVID-19 and emerging viral infections : the case for interferon lambda", J Exp Med, 217, pp.217~ (2020)
112. Broggi A, "Type III interferons disrupt the lung epithelial barrier upon viral recognition", Science, 369, pp.706~712 (2020)

관련 논문AI추천